Navigation Links
Echo Therapeutics to Present at RedChip Small-Cap Investor Conference
Date:2/5/2008

FRANKLIN, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a specialty pharmaceuticals and diabetes management company, announced today that Patrick T. Mooney, M.D, Chairman and Chief Executive Officer, will present at the RedChip Small-Cap Investor Conference on February 7, 2008 at 3:50 pm Mountain Standard Time (5:50 pm Eastern Standard Time). The conference will be held at the Four Seasons Resort in Scottsdale, Arizona. A live video webcast of the presentation will be available on the RedChip Small-Cap Investor Conference website, http://www.visualwebcaster.com/RedChipfeb2008/. A replay of the webcast and the corresponding presentation will be available on Echo Therapeutics' website shortly following the live presentation.

About Echo Therapeutics

Echo Therapeutics is a platform-enabled, specialty pharmaceuticals and diabetes management company leveraging its expertise in transdermal science to develop and commercialize non-invasive specialty pharmaceutical products and medical devices. Echo's Symphony(TM) CTGM System is a next generation needle- free, wireless, continuous transdermal glucose monitoring (CTGM) system for diabetes home use and emerging hospital critical care markets. Symphony is designed to provide on-demand glucose data conveniently, continuously and cost-effectively. Symphony incorporates Echo's patented feedback mechanism for optimal skin permeation control and its continuous transdermal biosensor. With Symphony, Echo is focused on changing the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care settings. Echo is also marshalling the potential of its patented AzoneTS(TM) transdermal drug delivery technology to build an extensive pipeline of advanced topical reformulations of FDA-approved products in accordance with the FDA's Section 505(b)(2) guidelines. Echo has submitted a New Drug Application (NDA) to the FDA for the approval of its lead AzoneTS-based product candidate, Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses.

Forward-Looking Statements

This press release contains forward-looking information that involves risks and uncertainties, including statements regarding Echo's development plans, objectives, expectations and intentions, including, without limitation, statements regarding the Company's Symphony and AzoneTS product candidates. Factors that could adversely affect Echo's business and prospects are described in the Company's filings with the Securities and Exchange Commission. Echo expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such statement is based.

Investor Relations Contacts:

Patrick T. Mooney, M.D.

Chairman & CEO

Echo Therapeutics

508-530-0329

Lilian Stern

Stern Investor Relations

212-362-1200


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology
2. Velcura Therapeutics, Inc. Teams with International Discovery Sourcing Consultants to Develop New Therapeutic Molecules for Cancer and Bone Disease
3. Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
4. Taligen Therapeutics Secures Series B Financing
5. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
6. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
7. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
8. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
9. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
10. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... 04, 2016 , ... PBI-Gordon Corporation is pleased to announce Doug Obermann has ... his career at PBI-Gordon in February 1988, after finishing his masters in agronomy from ... from customer service to national product manager, to helping develop, name and launch many ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... enterprise talent development, skill-building and compliance training platform on mobile devices, today released ... Overview of Regulatory Requirements for Medical Devices. The course is essential for owners ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... of Dr. Nancy Gillett to its Board of Directors. Dr. Gillett recently retired ... Corporate Executive Vice President and Chief Scientific Officer. A board-certified veterinary pathologist, Dr. ...
(Date:5/3/2016)... - And Other Rising Companies - a ... Biologics  - Biosimilar Drug Producers - Your ... Who are the most important and promising ... potentials? Discover, in our updated survey, organisations, outlooks from ... forecasting. Visiongain,s new study analyses ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
(Date:3/15/2016)... , March 15, 2016 Yissum Research ... the technology-transfer company of the Hebrew University, announced today ... remote sensing technology of various human biological indicators. Neteera ... $2.0 million from private investors. ... on the detection of electromagnetic emissions from sweat ducts, ...
Breaking Biology News(10 mins):